Home › Washington › Bills
Bills

Washington Congressional Bills

Browse federal bills sponsored by your state's delegation.

Bill results

in committee · Washington · House Mar 4, 2021

HR 1587: Medicare Audiologist Access and Services Act of 2021

Medicare Audiologist Access and Services Act of 2021 This bill provides for Medicare coverage of certain audiologist services. Specifically, the bill expands coverage to include diagnostic and treatment services that are furnished by audiologists and that would otherwise be covered if provided by a physician, including incidental services, regardless of whether such services are provided pursuant to a referral from, or under the supervision of, a physician or other health care practitioner.
Tom Rice (R) · 54 co-sponsors
in committee · Washington · House Mar 4, 2021

HR 1553: Ellie’s Law

Ellie Helton, Lisa Colagrossi, Kristen Shafer Englert, Teresa Anne Lawrence, and Jennifer Sedney Focused Research Act or Ellie's Law This bill authorizes appropriations for the National Institute of Neurological Disorders and Stroke to conduct or support research on unruptured brain aneurysms in a patient population diversified by age, sex, and race.
Yvette D. Clarke (D) · 43 co-sponsors
in committee · Washington · House Mar 4, 2021

HR 1551: Nutrition CARE Act of 2021

Nutrition Counseling Aiding Recovery for Eating Disorders Act of 2021 or the Nutrition CARE Act of 2021 This bill provides for Medicare coverage of medical nutrition therapy services for individuals with eating disorders. Such services must be furnished by a registered dietitian or nutrition professional pursuant to a referral from a physician, psychologist, or other authorized mental health professional.
Judy Chu (D) · 92 co-sponsors
in committee · Washington · House Mar 4, 2021

HR 1588: Hydropower Clean Energy Future Act

Hydropower Clean Energy Future Act This bill expands provisions related to renewable energy, including hydropower production, and revises the hydropower licensing process. The bill updates federal renewable purchase requirements. Specifically, the bill requires the federal government to purchase an increasing amount of renewable energy, including hydropower. By 2026, 25% of the total amount of electric energy the federal government consumes during any fiscal year must be renewable energy. In addition, the bill also provides an expedited licensing process for next-generation hydropower projects. The bill also revises requirements concerning the environmental review of certain hydroelectric power projects, including by designating the Federal Energy Regulatory Commission as the lead agency for the purposes of environmental reviews, allowing certain categories of projects to be exempted from such reviews, and establishing deadlines to complete such reviews. Finally, the bill establishes requirements about resolving (1) inconsistent or conflicting license terms, and (2) federal interagency disputes or disputes among federal and state agencies.
Cathy McMorris Rodgers (R) · 8 co-sponsors
in committee · Washington · House Mar 4, 2021

HR 1577: Treat and Reduce Obesity Act of 2021

Treat and Reduce Obesity Act of 2021 This bill expands Medicare coverage of intensive behavioral therapy for obesity. Specifically, the bill allows coverage for therapy that is provided by (1) a physician who is not a primary care physician; or (2) other health care providers (e.g., physician assistants and nurse practitioners) and approved counseling programs, if provided upon a referral from, and in coordination with, a physician or primary care practitioner. Currently, such therapy is covered only if provided by a primary care practitioner. The bill also allows coverage under Medicare's prescription drug benefit of drugs used for the treatment of obesity or for weight loss management for individuals who are overweight.
Ron Kind (D) · 154 co-sponsors
in committee · Washington · House Mar 4, 2021

HR 276: Congressional Oversight of Unjust Policing Act

Congressional Oversight of Unjust Policing Act This bill establishes the U.S. Commission on Unjust Policing to investigate law enforcement activities and decisions related to the security breach at the U.S. Capitol on January 6, 2021. Specifically, the commission must investigate decisions made by leadership of the U.S. Capitol Police (USCP), the Federal Bureau of Investigation, the U.S. Secret Service, and the Department of Homeland Security leading up to and during the siege at the Capitol, including an assessment of whether conscious and unconscious bias was a factor in the miscalculation of the risk posed by protesters to Members of Congress and their staff. The commission must also investigate whether current USCP officers have ties to white supremacist and other extremist groups, movements, and organizing efforts, and whether any USCP officers neglected their duty and colluded with protestors or other law enforcement entities. Further, the commission must recommend specific measures and reforms related to realigning (1) USCP priorities and practice to address disparate use of force and surveillance targets in and around the Capitol; and (2) USCP recruitment, hiring, and retention policies and practices to address conscious and unconscious biases.
Jamaal Bowman (D) · 30 co-sponsors
in committee · Washington · House Mar 4, 2021

HR 262: Federal Death Penalty Prohibition Act

Federal Death Penalty Prohibition Act This bill prohibits the imposition of a death penalty sentence for a violation of federal law. A person sentenced to death before enactment of this bill must be resentenced.
Ayanna Pressley (D) · 79 co-sponsors
in committee · Washington · House Mar 4, 2021

HR 151: Preventing Future Pandemics Act of 2021

Preventing Future Pandemics Act of 2021 This bill establishes measures to address global public health risks posed by wildlife markets, which are commercial markets that sell or slaughter wildlife for human consumption as food or medicine in communities where alternative nutritional or protein sources are available. Specifically, the bill prohibits importing, exporting, purchasing, or selling live wild animals in the United States for human consumption as food or medicine. The Department of the Interior must hire, train, and deploy at least 50 new U.S. Fish and Wildlife Service law enforcement attachés around the world, and the U.S. Agency for International Development must increase specified activities to address the threats and causes of zoonotic (animal-to-human transmission) disease outbreaks. Additionally, the United States must work with other United Nations member states to urge a global ban on commercial wildlife markets and enforcement of laws to end wildlife trafficking. Further, the President may impose sanctions against a foreign country or foreign nationals that the Department of State has determined are taking certain actions that enable or facilitate commercial wildlife markets. Among other reports required by the bill, the National Academies of Sciences, Engineering, and Medicine must conduct a study and submit a report that includes an evaluation of (1) the impact that consumption of terrestrial wildlife as food or medicine has on the transmission of novel viral and other pathogens, (2) the role of consuming terrestrial wildlife as food or medicine in the transmission of microbes from animals to humans, and (3) the conditions at live wildlife markets that lead to this transmission.
Mike Quigley (D) · 188 co-sponsors
in committee · Washington · House Mar 4, 2021

HR 153: Protecting Consumer Access to Generic Drugs Act of 2021

Protecting Consumer Access to Generic Drugs Act of 2021 This bill prohibits the manufacturer of a brand-name, generic, or biosimilar drug from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product. Specifically, such an agreement shall, with some exceptions, be a violation of the bill if the filer of a subsequent application to market a drug or biological product receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the subsequent drug or biological product. (Typically, a subsequent application seeks to market a generic or biosimilar version of a patented drug or biological product.) Penalties for violations of the bill include civil penalties and loss of the 180-day exclusivity period for a generic drug. The Federal Trade Commission (FTC) shall have exclusive authority to litigate to enforce the bill. When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing or sale of a drug, the manufacturers shall certify that the material they have given the FTC concerning the agreement contains (1) the complete agreement; and (2) any agreements related to the main agreement, including descriptions of any oral agreements or representations.
Bobby L. Rush (D) · 18 co-sponsors
in committee · Washington · Senate Mar 3, 2021

SJRES 1: A joint resolution removing the deadline for the ratification of the equal rights amendment.

This joint resolution eliminates the deadline for the ratification of the Equal Rights Amendment, which prohibits discrimination based on sex. The amendment was proposed to the states in House Joint Resolution 208 of the 92nd Congress, as agreed to in the Senate on March 22, 1972. The amendment shall be part of the Constitution whenever ratified by the legislatures of three-fourths of the states.
Benjamin L. Cardin (D) · 51 co-sponsors
Showing 7,645 to 7,656 of 7,962 bills